Welcome to the 2nd Annual Oligonucleotides for CNS Summit
With Biogen investing millions in Ionis' efforts to weaponize ASOs against SMA, Stoke Therapeutics collaborating with Acadia Pharmaceuticals to supercharge the development of RNA-Based treatments for genetic neurodevelopmental diseases and the global oligonucleotide therapeutics market set to experience unprecedented growth, there’s never been a more opportune moment for biopharma to expand their oligonucleotide pipelines into the untapped potential of the CNS.
Dedicated to providing you with the insights you need to create clinically defining oligonucleotide therapeutics, the 2nd Oligonucleotides for CNS Summit will unite a multinational faculty of experts from Eli Lilly, Roche, Biogen, Alnylam, Servier, Stoke Therapeutics and more to divulge the critical insights you need to accelerate your oligonucleotide therapeutic development against Alzheimer’s, Huntington’s, Glioblastoma and more!
From learning how to manipulate oligonucleotide chemistry to maximize therapeutic potency to more effectively collaborating with CROs/CMOs to manufacture therapies in line with regulatory standards and exploring antibodies, small molecules & nanoparticles for movement across the blood brain barrier, this focused industry forum will give you the chance to gain back-to-back insights on the science propelling oligonucleotide therapeutics forward in 2022.
As industry turn their heads towards the CNS in a bid to capitalize on its strategic opportunity, join 80+ ASO and RNA-based therapeutic experts at this unique forum for a dynamic mix of formal presentations, audience discussions, panel discussions and organized networking and leave with the expertise your team needs to optimize your oligonucleotides approach in the CNS this year.
Want to learn more about our brand new 2022 agenda and expert speaker faculty?
Expert Speakers Include:
Senior Director & Head of Oligonucleotide Process Development
Chief Scientific Officer
Q State Bio
Senior Vice President, Innovation Chemistry
Reviews From the Hanson Wade Oligonucleotides Community:
“It was a very well-organized, pertinent and industry-focused event. I greatly enjoyed the science and learned from the experience of the speakers.” -Yashodhan Chinchore, Senior Scientist, Astellas Innovation Management
“It was overall a great summit to learn and engage with like-minded people working towards CNS delivery of oligonucleotides.” – Riaz Alam, Consultant Biologist – Biotechnology Discovery Research, Eli Lilly & Company
“Great setting to catch up on the latest developments on oligonucleotides therapies. The round tables were great and very informative.” – Ana Santos, Senior Scientist - Translational Research, VIB